TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07174570: Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Sponsor: Emory University · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 39 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT07174570 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07174570 Rescue Dossier →